420 with CNW — NORML Analysis Reveals Significant Uptick in Cannabis Research in 2022
Researchers have been busy, publishing more than 4,300 scientific papers on marijuana, making 2022’s tally a new record for annual cannabis research published. It is said that cannabis and its components are the most understudied, yet they have attracted plenty of researchers’ attention in current times. With cannabis being a federally illicit substance, studying it would be most agreeable to most people, especially given that more states are legalizing marijuana in one form or another.
Largely, a societal misconception has it that cannabis is not extensively studied hence a lot of myths carry the day as far as policy reforms are concerned.
An analysis targeting the federal Pubmed.gov site shows that more than 4,300 scientific research publications have been made available worldwide targeting cannabis and its derivatives. This number of articles exceeds last year’s 4,200 articles.
The claims that marijuana has not been amply studied falls flat when such a sizeable annual tally of research papers is considered, and interest in studying cannabis has sharply increased recently even as we try to understand the plant and its potent components, including pharmacokinetics and pharmacodynamics, as well as its effects on the user and society at large, according to a blog post penned by Paul Armentano, NORML’s deputy director.
Armentano added that politicians need to cease assessing cannabis negatively and engage in evidence-based discussions about cannabis and policies that bring to light more objective or factual information about the plant. Advocates looking to support the marijuana bill have merged with prohibitionists in support of extensive cannabis research. This is emphasized due to President Joseph Biden assenting to a standalone bill streamlining marijuana/cannabis studies.
Separately, the House and Senate passed a similar bill on cannabis research in late 2020 though none of those bills made it to President Trump’s desk for approval by the end of his tenure in office. Researchers in Congress have released a report detailing challenges encountered because of the prohibition from federal governments and the possible options available to the lawmakers to address.
The Drug Enforcement Administration (DEA) has also stepped in to approve new marijuana growers to boost the supply for these studies. Finally, the National Institute on Drug Abuse published an appeal for applications from authorized growers as new contractors to supply the plant to the agency for research purposes.
Biden signed a large-scale framework legislation that contained provisions which would allow researchers to study the real plant purchased by consumers from state-licensed suppliers instead of using government-grown cannabis only.
NIDA director Nora Volkow has admitted that scientists have been limited in getting research data for the study of cannabis and it would be good to establish a body to initiate a policy change that allows access to marijuana products from the state-legal outlets.
As more research finds its way into the public domain, perceptions are likely to undergo a dramatic shift, and it may not be long before many people take up the legal cultivation of cannabis indoors using the latest compact indoor grow equipment from manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX).
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Researchers have been busy, publishing more than 4,300 scientific papers on marijuana, making 2022’s tally a new record for annual cannabis research published. It is said that cannabis and its components are the most understudied, yet they have attracted plenty of researchers’ attention in current times. With cannabis being a federally illicit substance, studying it would be most agreeable to most people, especially given that more states are legalizing marijuana in one form or another.
Largely, a societal misconception has it that cannabis is not extensively studied hence a lot of myths carry the day as far as policy reforms are concerned.
An analysis targeting the federal Pubmed.gov site shows that more than 4,300 scientific research publications have been made available worldwide targeting cannabis and its derivatives. This number of articles exceeds last year’s 4,200 articles.
The claims that marijuana has not been amply studied falls flat when such a sizeable annual tally of research papers is considered, and interest in studying cannabis has sharply increased recently even as we try to understand the plant and its potent components, including pharmacokinetics and pharmacodynamics, as well as its effects on the user and society at large, according to a blog post penned by Paul Armentano, NORML’s deputy director.
Armentano added that politicians need to cease assessing cannabis negatively and engage in evidence-based discussions about cannabis and policies that bring to light more objective or factual information about the plant. Advocates looking to support the marijuana bill have merged with prohibitionists in support of extensive cannabis research. This is emphasized due to President Joseph Biden assenting to a standalone bill streamlining marijuana/cannabis studies.
Separately, the House and Senate passed a similar bill on cannabis research in late 2020 though none of those bills made it to President Trump’s desk for approval by the end of his tenure in office. Researchers in Congress have released a report detailing challenges encountered because of the prohibition from federal governments and the possible options available to the lawmakers to address.
The Drug Enforcement Administration (DEA) has also stepped in to approve new marijuana growers to boost the supply for these studies. Finally, the National Institute on Drug Abuse published an appeal for applications from authorized growers as new contractors to supply the plant to the agency for research purposes.
Biden signed a large-scale framework legislation that contained provisions which would allow researchers to study the real plant purchased by consumers from state-licensed suppliers instead of using government-grown cannabis only.
NIDA director Nora Volkow has admitted that scientists have been limited in getting research data for the study of cannabis and it would be good to establish a body to initiate a policy change that allows access to marijuana products from the state-legal outlets.
As more research finds its way into the public domain, perceptions are likely to undergo a dramatic shift, and it may not be long before many people take up the legal cultivation of cannabis indoors using the latest compact indoor grow equipment from manufacturers such as Advanced Container Technologies Inc. (OTC: ACTX).
NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
